Skip to main content

STUDY: RISK FOR SKIN CANCER INVOLVES NUMEROUS GENETIC FACTORS

Image result for NUMEROUS GENETIC FACTORS
It’s common knowledge that excessive UV exposure from sunlight raises your chances for skin cancer, but predicting whether someone will actually develop skin cancer remains difficult. In a new research report, scientists from the University of Alabama at Birmingham (UAB) and the University of Wisconsin-Madison show that the risk for skin cancer involves numerous genetic factors including family history, ethnicity, and genetic variations specific to each individual. Using these factors, the researchers developed a more precise model for assessing risk, which is published in the December 2012 issue of the journal GENETICS (http://www.genetics.org).
“We hope this study will ultimately contribute toward a better understanding of the genetics of complex traits and diseases,” said Ana Inés Vázquez, Ph.D., lead author of the study from UAB’s Department of Biostatistics. “Such an understanding is essential for the development of methods that can be used for early and improved prediction of genetic predisposition to diseases.”
To make this discovery, the scientists used phenotypic and genetic information from more than 5,000 familial participants in the Framingham Heart Study to develop various models for assessing skin cancer risk. The researchers’ most basic risk evaluation model included standard risk factors such as sex. Additional predictive models were developed by adding information on family history, ethnicity, and data from 41,000 genetic markers across the human genome. The predictive power of each model was evaluated, with the best prediction accuracy obtained from models that include all predictive risk factors — those standard risk factors plus family history, ethnicity and genetic markers.
“Although there is no doubt that sun exposure increases your risk for skin cancer,” said Mark Johnston, Editor-in-Chief of the journal GENETICS, “it isn’t clear how much of a risk it poses to each individual. This new model for assessing risk should prove useful to health care providers and public health officials, who play a crucial role in educating people about preventing skin cancer.”

Comments

Post a Comment

Popular posts from this blog

HYFRECATORS AND INTERFERENCE WITH IMPLANTABLE CARDIAC DEVICES

Investigation of Hyfrecators and They are In Vitro Interference with Implantable Cardiac Devices CHRISTOPHER WEYER, DO,* RONALD J. SIEGLE, MD,†‡ AND GUILLAUME GIRARD P. ENG, EMI-EMC§ BACKGROUND Guidelines exist for minimizing potential electromagnetic interference (EMI) with electrosurgical equipment in patients with cardiac rhythm management (CRM) devices. These guidelines encompass all electrosurgical devices but are not specific for hyfrecators. OBJECTIVE To investigate the potential interference of CRM devices by hyfrecators. MATERIALS AND METHODS Using a collagen-based saline gel, three implantable pulse generators (pacemakers) and three implantable cardioverter defibrillators were tested to measure the EMI from two commonly used hyfrecators. The six devices were tested using the hyfrecator under normal use settings and on maximum power. RESULTS Hyfrecators did not interfere with defibrillators and affected pacemakers only when used in close proximity to the devi...
Post a Comment
Read more

NEW DRUG THERAPY FOR BCC

Genentech Submits New Drug Application to FDA for Vismodegib for Rare Form of Advanced Skin Cancer Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the company has submitted a New Drug Application for vismodegib to the U.S. Food and Drug Administration (FDA) for the treatment of people with advanced basal cell carcinoma (BCC) for whom surgery is considered inappropriate. Vismodegib is an investigational, oral, targeted medicine designed to selectively inhibit signaling in the Hedgehog pathway, which is implicated in more than 90 percent of BCC cases. BCC is the most common type of skin cancer, which is generally considered curable by surgery. However, when it advances, BCC can cause disfiguring and debilitating effects and can ultimately be life-threatening. “We are excited by the pivotal study results that showed vismodegib substantially reduced tumor size or healed lesions for people with this rare skin cancer, which has no approved ...
Post a Comment
Read more

TRANSACTION AND MELANOMA SURVIVAL

The rate of melanoma transaction with various biopsy techniques and the influence of tumor transaction on patient survival Mohsin Mir, MD, C. Stanley Chan, MD, Farhan Khan, MD, MBA, Bhuvaneswari Krishnan, MD, Ida Orengo, MD, and Theodore Rosen, MD Houston, Texas Background: Depth of melanoma invasion is critical because it dictates patient treatment and prognosis. Recent reports indicate melanoma transection with initial biopsy does not impact patient survival; however, tumor transaction can lead to misdiagnosis and inaccurate staging. Objective: This study assessed the rate of melanoma transaction with various biopsy techniques and the impact of tumor transaction on patient survival. Methods: We conducted a retrospective review of all melanoma cases at our institution between 2000 and 2008. Of the 490 melanoma cases identified, 479 met inclusion criteria for the study. The transaction rates of biopsy techniques were determined. Cases of transected ...
Post a Comment
Read more